The CLSA genomic subcohort provides a large-scale resource for studying genetic factors in aging, cognitive decline, and cardiovascular diseases.
Supports expanded genomic inquiry into aging-related CVD; should not yet alter clinical management.
The CLSA overall is ongoing. Follow-up data will continue to be collected from participants in the current genomic subcohort, including the DNA methylation and metabolomic data. Ongoing studies focus on elucidating the role of genetic factors in cognitive decline and cardiovascular diseases. This genomic data resource is available on request through the CLSA data access application process.
No takes yet. Share an insight, caveat, or question.
Forgetta et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: